Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Young-Suk Lim

Showing results (11-20 of 373) with videos related to

Pageof 38
Sort By:
The Journal of Infectious Diseases|November 21, 2017
Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive TherapyJonggi Choi, Young-Suk Lim
The Kaohsiung Journal of Medical Sciences|January 27, 2021
Secondary prevention of hepatitis B virus-related hepatocellular carcinoma with current antiviral therapiesJonggi Choi, Young-Suk Lim
Ebiomedicine|December 17, 2016
Genetic-based Risk Assessment for Hepatocellular Carcinoma in Patients with Hepatitis C: Where Do We Stand?Jonggi Choi, Young-Suk Lim
Hepatology (Baltimore, Md.)|October 6, 2020
ReplyJonggi Choi, Young-Suk Lim
Journal of Hepatology|July 29, 2019
Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no directionJonggi Choi, Young-Suk Lim
Clinical and Molecular Hepatology|November 29, 2017
Lamivudine: fading into the mists of timeJonggi Choi, Young-Suk Lim
Alimentary Pharmacology & Therapeutics|April 1, 2022
Editorial: does TAF have a better or worse safety profile than TDF, to treat hepatitis B? Authors' replyYoung-Suk Lim, Pietro Lampertico
Hepatology (Baltimore, Md.)|June 30, 2020
REPLYJonggi Choi, Young-Suk Lim
Alimentary Pharmacology & Therapeutics|July 14, 2020
Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Authors' replyGi-Ae Kim, Young-Suk Lim
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 17, 2024
ReplyWon-Mook Choi, Young-Suk Lim
Pageof 38

Showing results (11-20 of 373) with videos related to

Sort By:
Pageof 38
The Journal of Infectious Diseases|November 21, 2017
Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive TherapyJonggi Choi, Young-Suk Lim
The Kaohsiung Journal of Medical Sciences|January 27, 2021
Secondary prevention of hepatitis B virus-related hepatocellular carcinoma with current antiviral therapiesJonggi Choi, Young-Suk Lim
Ebiomedicine|December 17, 2016
Genetic-based Risk Assessment for Hepatocellular Carcinoma in Patients with Hepatitis C: Where Do We Stand?Jonggi Choi, Young-Suk Lim
Hepatology (Baltimore, Md.)|October 6, 2020
ReplyJonggi Choi, Young-Suk Lim
Journal of Hepatology|July 29, 2019
Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no directionJonggi Choi, Young-Suk Lim
Clinical and Molecular Hepatology|November 29, 2017
Lamivudine: fading into the mists of timeJonggi Choi, Young-Suk Lim
Alimentary Pharmacology & Therapeutics|April 1, 2022
Editorial: does TAF have a better or worse safety profile than TDF, to treat hepatitis B? Authors' replyYoung-Suk Lim, Pietro Lampertico
Hepatology (Baltimore, Md.)|June 30, 2020
REPLYJonggi Choi, Young-Suk Lim
Alimentary Pharmacology & Therapeutics|July 14, 2020
Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Authors' replyGi-Ae Kim, Young-Suk Lim
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 17, 2024
ReplyWon-Mook Choi, Young-Suk Lim
Pageof 38